Novartis study shows benefits of Kymriah in hard-to-treat cancer

Novartis has announced the findings of a new study showing the benefits of Kymriah in the treatment of a difficult-to-treat form of cancer.

Data from the JULIET study demonstrated sustained responses associated with Kymriah suspension for intravenous infusion among adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

An overall response rate of 53 percent was achieved with Novartis' drug, with 40 percent achieving a complete response and 14 percent achieving a partial response among patients with three or more months of follow-up or earlier discontinuation.

DLBCL patients involved in this trial had been through multiple rounds of chemotherapy and many had unsuccessful stem cell transplants, meaning this patient group has few treatment options and a generally poor prognosis.

Dr Samit Hirawat, head of global oncology drug development at Novartis, said: "We look forward to continuing to work with health authorities to bring Kymriah to patients with relapsed or refractory DLBCL."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.